Opinion|Videos|April 1, 2026
Building Upon the Lenalidomide/Rituximab Backbone in R/R Follicular Lymphoma
Author(s)Loretta J. Nastoupil, MD, Amitkumar Mehta, MD
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss methods of building on the lenalidomide/rituximab backbone in relpased/refractory follicular lymphoma.
Advertisement
Episodes in this series
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss how the lenalidomide/rituximab (R²) backbone continues to serve as a foundation for novel combination strategies in relapsed/refractory follicular lymphoma. Nastoupil reviews the clinical impact of adding agents such as tafasitamab to R² and how recent approvals are shaping practice. Mehta underscores how updated NCCN Guidelines and emerging triplet regimens are influencing second-line treatment decision-making.
Advertisement
Related to this article
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Roswell Park researchers showed that blocking a novel metabolic pathway severely restricts tumor proliferation.
Dostarlimab monotherapy met the primary end point of sustained clinical complete response at 12 months in the phase 2 AZUR-1 trial.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The decision does not reflect new concerns about the clinical efficacy or safety data from the phase 3 CARES-310 trial.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.
Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
4
Dive Into Key Data and Presentations From EHA 2026
5